Abraham V - Search Results

1

Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.

Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, Høyer-Hansen G, Craik CS, Vincenti F. Harel E, et al. Among authors: abraham v. Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21. Clin Transplant. 2019. PMID: 30689221

2

Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.

Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F. Harel E, et al. Among authors: abraham v. Transplantation. 2020 Jan;104(1):54-60. doi: 10.1097/TP.0000000000002930. Transplantation. 2020. PMID: 31449183 Free PMC article.

3

Implementation of a human podocyte injury model of chronic kidney disease for profiling of renoprotective compounds.

Abraham VC, Miller LN, Pratt SD, Putman B, Kim L, Gopalakrishnan SM, King A. Abraham VC, et al. Eur J Pharmacol. 2017 Nov 15;815:219-232. doi: 10.1016/j.ejphar.2017.09.006. Epub 2017 Sep 9. Eur J Pharmacol. 2017. PMID: 28899697

4

Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans.

Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ. Abraham VC, et al. J Biomol Screen. 2008 Jul;13(6):527-37. doi: 10.1177/1087057108318428. Epub 2008 Jun 19. J Biomol Screen. 2008. PMID: 18566484

5

A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injury.

Zhu CZ, Gopalakrishnan S, Doyle K, Nikkel AL, Olson L, Abraham VC, Leys L, Widomski D, Salte K, Putman B, Pratt S, Ma J, Su Z, Gopalakrishnan M, Lee CH, McGaraughty SP. Zhu CZ, et al. Eur J Pharmacol. 2016 Oct 5;788:1-11. doi: 10.1016/j.ejphar.2016.06.012. Epub 2016 Jun 8. Eur J Pharmacol. 2016. PMID: 27288879

6

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.

Wilsbacher JL, Cheng M, Cheng D, Trammell SAJ, Shi Y, Guo J, Koeniger SL, Kovar PJ, He Y, Selvaraju S, Heyman HR, Sorensen BK, Clark RF, Hansen TM, Longenecker KL, Raich D, Korepanova AV, Cepa S, Towne DL, Abraham VC, Tang H, Richardson PL, McLoughlin SM, Badagnani I, Curtin ML, Michaelides MR, Maag D, Buchanan FG, Chiang GG, Gao W, Rosenberg SH, Brenner C, Tse C. Wilsbacher JL, et al. Among authors: abraham vc. Mol Cancer Ther. 2017 Jul;16(7):1236-1245. doi: 10.1158/1535-7163.MCT-16-0819. Epub 2017 May 3. Mol Cancer Ther. 2017. PMID: 28468779

7

Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research.

Towne DL, Nicholl EE, Comess KM, Galasinski SC, Hajduk PJ, Abraham VC. Towne DL, et al. J Biomol Screen. 2012 Sep;17(8):1005-17. doi: 10.1177/1087057112450050. Epub 2012 Jun 15. J Biomol Screen. 2012. PMID: 22706350

8

Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.

Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE. Phillips DC, et al. Cancer Res. 2021 Jun 15;81(12):3402-3414. doi: 10.1158/0008-5472.CAN-20-2178. Epub 2021 Mar 9. Cancer Res. 2021. PMID: 33687950

9

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.

Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D. Hopkins TA, et al. Mol Cancer Res. 2019 Feb;17(2):409-419. doi: 10.1158/1541-7786.MCR-18-0138. Epub 2018 Nov 14. Mol Cancer Res. 2019. PMID: 30429212

10

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, Elmore SW. Chen J, et al. Among authors: abraham v. Mol Cancer Ther. 2011 Dec;10(12):2340-9. doi: 10.1158/1535-7163.MCT-11-0415. Epub 2011 Sep 13. Mol Cancer Ther. 2011. PMID: 21914853

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters